1. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma
- Author
-
STAMATIS J. KARAKATSANIS, MARIA BOUZANI, ARGYRIS SYMEONIDIS, MARIA K. ANGELOPOULOU, SOTIRIOS G. PAPAGEORGIOU, MICHAIL MICHAIL, GABRIELLA GAINARU, GEORGIA KOURTI, SOTIRIOS SACHANAS, CHRISTINA KALPADAKIS, EIRINI KATODRITOU, THEONI LEONIDOPOULOU, IOANNIS KOTSIANIDIS, ELEFTHERIA HATZIMICHAEL, MARIA KOTSOPOULOU, MARIA DIMOU, ELENI VARIAMIS, DIMITRIOS BOUTSIS, NICK KANELLIAS, MARIA N. DIMOPOULOU, EVRIDIKI MICHALI, GEORGE KARIANAKIS, PANTELIS TSIRKINIDIS, CHRYSSA VADIKOLIA, CHRISTOS POZIOPOULOS, ANNA PIGADITOU, EFFIMIA VRAKIDOU, THEOPHANIS ECONOMOPOULOS, LYDIA KYRIAZOPOULOU, MARINA P. SIAKANTARIS, MARIE-CHRISTINE KYRTSONIS, KONSTANTINOS ANARGYROU, MARIA PAPAIOANNOU, EVDOXIA HATJIHARISSI, ELISSAVET VERVESSOU, MARIA TSIROGIANNI, MARIA PALASSOPOULOU, EKATERINI STEFANOUDAKI, PANAYIOTIS ZIKOS, PANAYIOTIS TSIRIGOTIS, GERASSIMOS TSOUROUFLIS, THEODORA ASSIMAKOPOULOU, EVGENIA VERROU, HELEN PAPADAKI, POLIXENI LAMPROPOULOU, MELETIOS-ATHANASIOS DIMOPOULOS, VASSILIKI PAPPA, KOSTAS KONSTANTOPOULOS, THEMIS KARMIRIS, PARASKEVI ROUSSOU, PANAYIOTIS PANAYIOTIDIS, GERASSIMOS A. PANGALIS, and THEODOROS P. VASSILAKOPOULOS
- Subjects
Pharmacology ,Cancer Research ,Lymphoma, B-Cell ,General Biochemistry, Genetics and Molecular Biology ,immune system diseases ,Doxorubicin ,Vincristine ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Prednisone ,Prospective Studies ,Rituximab ,Cyclophosphamide ,Research Article ,Retrospective Studies - Abstract
Background/Aim: Primary mediastinal large B-cell lymphoma (PMLBCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody rituximab into current therapeutic regimens. Evidence, however, on the optimal time interval between consecutive chemoimmunotherapy (CIT) cycles is still scarce. This study aimed to evaluate the efficacy outcomes of the more commonly administered 3-weekly regimens to the biweekly ones in a PMLBCL patients’ population, who were mostly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP-21) or R-CHOP-14. Patients and Methods: We retrospectively studied our cohort of consecutively treated PMLBCL patients, focusing on their treatment density, in order to determine possible differences in treatment outcomes. Results: CIT, in the form of both R-CHOP-21 as well as R-CHOP-14 (or similar regimens), is highly active in PMLBCL, with low rates of early treatment failure. In our cohort of patients, R-CHOP-14 did not result in a meaningful improvement of freedom from progression (FFP) or overall survival (OS). Conclusion: Both R-CHOP-14 and R-CHOP-21 are probably equally effective in PMLBCL, yet further, prospective, randomized studies are warranted to clarify whether dose-dense regimens can be associated with better disease control and long-term results.
- Published
- 2022